Announcements
- Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024
- Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
- Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
- Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
- Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024
- Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
- Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
- Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
- Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)
- Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing
More ▼
Key statistics
On Friday, Emergent BioSolutions Inc (0IGA:LSE) closed at 1.95, 31.76% above the 52 week low of 1.48 set on Feb 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 1.95 |
Average volume | 1.91k |
---|---|
Shares outstanding | 52.39m |
Free float | 51.41m |
P/E (TTM) | -- |
Market cap | 100.59m USD |
EPS (TTM) | -14.75 USD |
Data delayed at least 20 minutes, as of Apr 26 2024 15:02 BST.
More ▼